Progestogen · Hormone Replacement Therapy, Female Reproductive Agent, Luteal Phase Support
Also known as Micronized Progesterone, Progestin, P4
KDIGO 2024 + manufacturer label
1,656 branded formulations. Look up specific brands in the Drugs workspace.
Jan Aushadhi — generic available at GoI pharmacies
Progesterone is an endogenous steroid hormone and the primary natural progestogen. It binds to intracellular progesterone receptors (PR-A and PR-B isoforms) in target tissues, acting as a transcription factor to regulate gene expression. Key actions include: transformation of estrogen-primed endometrium to secretory phase, maintenance of pregnancy by suppressing uterine contractility and modulating immune tolerance at the maternal-fetal interface, negative feedback inhibition of gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH) secretion, and thermogenic effect (0.3-0.5°C basal temperature rise in luteal phase).
FDA PLLR: Natural progesterone is used for luteal phase support and preterm birth prevention — this is a therapeutic indication in pregnancy. No evidence of fetal harm at therapeutic doses. 17-OHPC is specifically approved for preterm birth prevention. Vaginal progesterone is category B (old system) with reassuring pregnancy data.
Progesterone is excreted in breast milk in small amounts. Natural progesterone is considered compatible with breastfeeding. No adverse effects reported in nursing infants.
Decreased progesterone plasma concentrations, leading to reduced efficacy.
Avoid co-administration. If unavoidable, consider increasing progesterone dose or using an alternative progestin. Monitor for signs of reduced progesterone effect.
Source: DDInter
Decreased progesterone plasma concentrations, leading to reduced efficacy (e.g., breakthrough bleeding, failure of contraception or hormone replacement therapy, increased risk of miscarriage in pregnancy support).
Avoid co-administration if possible. If unavoidable, consider increasing progesterone dose or using an alternative progestin that is less susceptible to CYP3A4 induction. Monitor for signs of reduced progesterone effect.
Source: DDInter
Clinical effect not specified
Source: DDInter
Increased progesterone plasma concentrations, potentially leading to increased progestogenic side effects (e.g., nausea, breast tenderness, fluid retention, mood changes).
Monitor for increased progesterone side effects. Consider reducing progesterone dose if side effects are bothersome or severe. Use with caution.
Source: DDInter
Increased progesterone plasma concentrations, potentially leading to increased progestogenic side effects (e.g., nausea, breast tenderness, fluid retention, mood changes).
Monitor for increased progesterone side effects. Consider reducing progesterone dose if side effects are bothersome or severe. Use with caution.
Source: DDInter
Decreased progesterone plasma concentrations, leading to reduced efficacy (e.g., breakthrough bleeding, failure of contraception or hormone replacement therapy, increased risk of miscarriage in pregnancy support).
Avoid co-administration if possible. If unavoidable, consider increasing progesterone dose or using an alternative progestin that is less susceptible to CYP3A4 induction. Monitor for signs of reduced progesterone effect.
Source: DDInter
Decreased progesterone plasma concentrations, leading to reduced efficacy (e.g., breakthrough bleeding, failure of contraception or hormone replacement therapy, increased risk of miscarriage in pregnancy support).
Avoid co-administration if possible. If unavoidable, consider increasing progesterone dose or using an alternative progestin that is less susceptible to CYP3A4 induction. Monitor for signs of reduced progesterone effect.
Source: DDInter
Decreased progesterone plasma concentrations, leading to reduced efficacy (e.g., breakthrough bleeding, failure of contraception or hormone replacement therapy, increased risk of miscarriage in pregnancy support).
Avoid co-administration if possible. If unavoidable, consider increasing progesterone dose or using an alternative progestin that is less susceptible to CYP3A4 induction. Monitor for signs of reduced progesterone effect.
Source: DDInter
Increased progesterone plasma concentrations, potentially leading to increased progestogenic side effects (e.g., nausea, breast tenderness, fluid retention, mood changes).
Monitor for increased progesterone side effects. Consider reducing progesterone dose if side effects are bothersome or severe. Use with caution.
Decreased progesterone plasma concentrations, leading to reduced efficacy (e.g., breakthrough bleeding, failure of contraception or hormone replacement therapy, increased risk of miscarriage in pregnancy support).
Avoid co-administration. If a patient is taking St. John's Wort, advise discontinuation or switch to an alternative antidepressant. Monitor for signs of reduced progesterone effect.
Source: DDInter
Clinical effect not specified
Source: DDInter
Increased progesterone plasma concentrations, potentially leading to increased progestogenic side effects (e.g., nausea, breast tenderness, fluid retention, mood changes).
Monitor for increased progesterone side effects. Consider reducing progesterone dose if side effects are bothersome or severe. Use with caution.
Source: DDInter
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-18 · House clinical team·Cockpit curated: 2026-05-18